The over 10,000 Jan Aushadhi Kendras across the country have led to savings of around Rs 7,416 crore for the citizens this financial year, Rajya Sabha was informed on Friday.
In a written reply in the Upper House, Minister of State for Chemicals and Fertilisers Bhagwanth Khuba said an unprecedented 150 times growth in annual sales has been witnessed by the scheme in the last 9 years.
"During the financial year 2022-23, Pharmaceuticals & Medical Devices Bureau of India (PMBI) has sold Jan Aushadhi medicines worth Rs 1,236 crore, with approx 40 per cent growth from the previous year and this has led to savings of approximately Rs 7,416 crore to the citizens," he noted.
The projected sales target for 2023-24 is Rs 1,400 crore and the scheme is growing at a very fast pace garnering public trust and confidence, Khuba said.
In all, during the past nine years, total savings have been estimated at more than Rs 23,000 crore for the citizens under this scheme, he stated.
On an average 10-12 lakh people visit Jan Aushadhi Kendras (JAKs) daily, the minister said. Khuba stated that as on November 30 this year, 10,006 Pradhan Mantri Bhartiya Janaushadhi Kendras (PMBJKs) have been opened covering 753 districts across the country.
Replying to a separate question, Khuba said India's total import of active pharmaceutical ingredients (APIs) for 2022-23 is worth Rs 36,229.15 crore and the quantity is 4,02,111.18 metric tonnes.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)